Gina Columbus | Authors


Neoadjuvant Therapy Impresses in I-SPY 2 Trial for Breast Cancer

July 04, 2020

According to investigators on the phase 2 I-SPY 2 study, the addition durvalumab plus olaparib to treatment with neoadjuvant paclitaxel led to better pathologic complete response rates in patients with high-risk, HER2-negative stage II/III breast cancer compared with paclitaxel alone.

Darolutamide Demonstrates Improved OS Over Placebo in Phase 3 ARAMIS Trial for Nonmetastatic CRPC

May 31, 2020

Patients with nonmetastatic castration-resistant prostate cancer receiving darolutamide plus androgen deprivation therapy had a 31% reduction for the risk of death compared with placebo and ADT, according to the results of the phase 3 ARAMIS trial’s preplanned final overall survival analysis presented during the 2020 ASCO Virtual Scientific Program.

Survival Benefits Are Maintained With Frontline Pembrolizumab/Axitinib in Advanced RCC

May 30, 2020

Progression-free and overall survival in patients with previously untreated, advanced renal cell carcinoma continued to show improvements with the combination of pembrolizumab and axitinib versus sunitinib in the phase 3 KEYNOTE-426 trial.